Cat. No.: DIA-0230216
Product Information | |
---|---|
CAS No. | 464930-42-5 |
Chemical Name | (3R)-3-(1,3-benzodioxol-5-yl)-N-[(6-methoxy-2-naphthalenyl)sulfonyl]-β-alanyl-4-[[(2R,6S)-2,6-dimethyl-1-piperidinyl]methyl]-N-methyl-N-(1-methylethyl)-D-phenylalaninamide, monohydrochloride |
Formula | C42H52N4O7S |
Molecular Weight | 793.40 |
PubChem CID | 44235958 |
SMILES | CC1CCCC(N1CC2=CC=C(C=C2)CC(C(=O)N(C)C(C)C)NC(=O)CC(C3=CC4=C(C=C3)OCO4)NS(=O)(=O)C5=CC6=C(C=C5)C=C(C=C6)OC)C.Cl |
Target | Zinc Finger |
Product Description | Bradykinin B1 receptor antagonist |
Format & Storage | |
---|---|
Purity | > 98% |
Shipping | Shipped on dry ice. |
Storage | Store at -20 °C. |
Solubility Overview | Soluble in DMSO to 25 mM |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.